↓ Skip to main content

Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients.

Overview of attention for article published in Annals of the Academy of Medicine Singapore, January 2023
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
7 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients.
Published in
Annals of the Academy of Medicine Singapore, January 2023
DOI 10.47102/annals-acadmedsg.2022302
Pubmed ID
Authors

Matilda Xinwei Lee, Siyu Peng, Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Ryan Yong Kiat Tay, Jiaqi Li, Areeba Tariq, Claire Xin Yi Goh, Ying Kiat Tan, Benjamin Kye Jyn Tan, Chong Boon Teo, Esther Chan, Melissa Ooi, Wee Joo Chng, Cheng Ean Chee, Carol LF Ho, Robert John Walsh, Maggie Wong, Yan Su, Lezhava Alexander, Sunil Kumar Sethi, Shaun Shi Yan Tan, Yiong Huak Chan, Kelvin Bryan Tan, Soo-Chin Lee, Louis Yi Ann Chai, Raghav Sundar

Abstract

Three doses of SARS-CoV-2 mRNA vaccines have been recommended for cancer patients to reduce the risk of severe disease. Anti-neoplastic treatment, such as chemotherapy, may affect long-term vaccine immunogenicity. Patients with solid or haematological cancer were recruited from 2 hospitals between July 2021 and March 2022. Humoral response was evaluated using GenScript cPASS surrogate virus neutralisation assays. Clinical outcomes were obtained from medical records and national mandatory-reporting databases. A total of 273 patients were recruited, with 40 having haematological malignancies and the rest solid tumours. Among the participants, 204 (74.7%) were receiving active cancer therapy, including 98 (35.9%) undergoing systemic chemotherapy and the rest targeted therapy or immunotherapy. All patients were seronegative at baseline. Seroconversion rates after receiving 1, 2 and 3 doses of SARS-CoV-2 mRNA vaccination were 35.2%, 79.4% and 92.4%, respectively. After 3 doses, patients on active treatment for haematological malignancies had lower antibodies (57.3%±46.2) when compared to patients on immunotherapy (94.1%±9.56, P<0.05) and chemotherapy (92.8%±18.1, P<0.05). SARS-CoV-2 infection was reported in 77 (28.2%) patients, of which 18 were severe. No patient receiving a third dose within 90 days of the second dose experienced severe infection. This study demonstrates the benefit of early administration of the third dose among cancer patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 14%
Student > Ph. D. Student 1 14%
Student > Bachelor 1 14%
Student > Master 1 14%
Unknown 3 43%
Readers by discipline Count As %
Unspecified 1 14%
Biochemistry, Genetics and Molecular Biology 1 14%
Nursing and Health Professions 1 14%
Immunology and Microbiology 1 14%
Medicine and Dentistry 1 14%
Other 0 0%
Unknown 2 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2023.
All research outputs
#6,464,474
of 25,711,518 outputs
Outputs from Annals of the Academy of Medicine Singapore
#75
of 452 outputs
Outputs of similar age
#117,713
of 476,366 outputs
Outputs of similar age from Annals of the Academy of Medicine Singapore
#2
of 7 outputs
Altmetric has tracked 25,711,518 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 452 research outputs from this source. They receive a mean Attention Score of 3.9. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 476,366 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.